24.25 USD
↗ 0.08 (0.33%)AT CLOSE (AS OF 07:31 PM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
Market: CLOSED
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $24.25 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 26, 2026.
Open?$24.16
High?$24.46
Low?$23.92
Prev. Close?$24.18
Volume?780.8K
Avg. Volume?1.8M
VWAP?$24.27
Rel. Volume?0.45x
Bid / Ask
Bid?$24.20 × 400
Ask?$24.72 × 100
Spread?$0.52
Midpoint?$24.46
Valuation & Ratios
Market Cap?2.7B
Shares Out?113.3M
Float?95.5M
Float %?86.5%
P/E Ratio?N/A
P/B Ratio?4.15
EPS?-$2.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
2.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?27
Momentum?75
Short Sent.?45
Piotroski F-Score?2/9Weak
Altman Z-Score?1.74Distress
Confidence?62%Moderate
Short InterestHigh
Short % of Float?19.91%High
Short Interest?19.0M
Days to Cover?9.1
Free Float95.5M
Avg Daily Volume2.1M
Settlement Date2026-08-14
Financial Health
Current Ratio?16.95Strong
Quick Ratio?16.95Strong
Cash Ratio?2.59Strong
Debt/Equity?0.54Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.15FAIR▾
Peers100
S&P43
P/S?38.64HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-7.3CHEAP▾
S&P97
EV/Sales?41.32HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-50.5%WEAK▾
S&P3
ROA?-30.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-335039000
Enterprise Value?$2.9B
Fundamentals ratios updated end of day